Reported cases in allergy centers
Of the 334 , 214 experienced any symptom in line with a possible allergic reaction after receiving a SARS-CoV-2 vaccination and five patients experienced symptoms in line with a possible allergic reaction after receiving the second vaccine dose. Out of these, 195 reactions occurred after the first application of an mRNA-based vaccine (157 Comirnaty®, and 38 Spikevax®) and eighteen reactions were reported from patients after application of a vector vaccine (Vaxzevria®) (figure 1). One patient had a reaction after the first dose of an unknown SARS-CoV-2 vaccination (Sup.Table 3). 115/334 included individuals had a positive allergy history and presented for the assessment of the risk to develop hypersensitivity reactions during SARS-CoV-2 vaccination. Of note, we only included those patients who underwent allergy testing in this analysis. Hundreds of patients more presented to the allergy centers with alleged SARS-CoV-2 vaccination reactions, but after taking a detailed history their symptoms were not considered to be allergic and further allergy work-up was omitted. Figure 2 shows a workflow of our study.